CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
pegylated interferon-alfa 2adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00241241
NCT00241241Phase 2Completed
CompareCT.gov

Multicenter Phase 2 Study of Efficacy and Safety of Pegylated Interferon-alfa 2a in Polycythemia Vera Patients

PV-Nord·interventional·Posted Oct 18, 2005·Updated Oct 21, 2015

In Brief

A Phase 2 clinical trial evaluating pegylated interferon-alfa 2a for Polycythemia Vera. Completed, across 5 sites.

Detailed Summary

Interferon alfa is an effective treatment of polycythemia vera (PV), but about 20% of patients discontinue their treatment because of side effects and treatment schedule (three times per week administration). The pegylated form of interferon alfa-2a has shown a better tolerance in hepatitis patients and is administered only once a week. The purpose of this study is to determine efficacy and safety of pegylated interferon alfa-2a in the treatment of PV patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycythemia Vera
CountriesFrance
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 18, 2005
Enrollment StartSep 1, 2004
Primary CompletionOct 1, 2006
Study CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 20.7 years ago

Interventions

pegylated interferon-alfa 2adrug